You've heard CRISPR called "molecular scissors." That's a decent start, but it skips the part that makes it revolutionary: the addressing system. In plain terms, CRISPR is two things working together — a cutting enzyme (Cas) and a short stretch of guide RNA that acts like a search query. The guide is written to match one specific sequence of DNA, and it drags the enzyme to that exact location before anything gets cut.
Think of it like find-and-replace in a document. The scissors alone would be useless — you'd cut at random. What makes editing possible is the guide: type in the target sequence, and the machinery goes to that one place out of three billion letters. That programmability, not the cutting, is the breakthrough.
The Broad Institute's granted patent US12644111B2, "CRISPR enzymes and systems" (issued June 2, 2026, inventor Feng Zhang and colleagues), sits in the patent family covering this machinery. Reading the record, you see the field is not one enzyme but a growing toolbox — different Cas proteins with different properties, claimed across many grants. CRISPR is a platform, and the patents map its expansion.
Here's where the scissors analogy breaks down, and it matters. Cutting the DNA is the easy part; what happens next is the cell's own repair machinery, which is messy. Sometimes it disables the gene (useful if you want it off), sometimes it can be coaxed to paste in a correction. A lot of modern gene-editing research — base editing, prime editing — exists precisely to avoid the blunt double-strand cut and edit more precisely. The platform keeps getting gentler.
Why does the patent layer matter to a general reader? Because CRISPR's commercial story has always been entangled with who owns the foundational tools. Therapies built on CRISPR — including approved ones — license machinery that traces back to grants like this Broad family. The science is shared widely; the right to commercialize it is not, and the patents are where that line is drawn.
So the next time you read that a company "used CRISPR" to do something, picture the real mechanism: a guide RNA programmed to a target, an enzyme that follows it, a cut, and a repair. And remember that the enzyme and the system around it are claimed property — the reason gene-editing headlines so often come with a footnote about licensing.